STAT3 Drives GFAP Accumulation and Astrocyte Pathology in a Mouse Model of Alexander Disease
Cells · 23.03.2023 · 12 (7) · 978
DOI: 10.3390/cells12070978 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 23.03.2023. Verfasst von Tracy L Hagemann und 5 weiteren Autor:innen. Beteiligte Einrichtung: Waisman Center, University of Wisconsin-Madison, Madison, WI 53705, USA. Hauptthemen laut MEDLINE: Alexander Disease, Glial Fibrillary Acidic Protein, STAT3 Transcription Factor. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NINDS NIH HHS, NIH NINDS.
Abstract (Originalsprache)
Alexander disease (AxD) is caused by mutations in the gene for glial fibrillary acidic protein (GFAP), an intermediate filament expressed by astrocytes in the central nervous system. AxD-associated mutations cause GFAP aggregation and astrogliosis, and GFAP is elevated with the astrocyte stress response, exacerbating mutant protein toxicity. Studies in mouse models suggest disease severity is tied to Gfap expression levels, and signal transducer and activator of transcription (STAT)-3 regulates Gfap during astrocyte development and in response to injury and is activated in astrocytes in rodent models of AxD. In this report, we show that STAT3 is also activated in the human disease. To determine whether STAT3 contributes to GFAP elevation, we used a combination of genetic approaches to knockout or reduce STAT3 activation in AxD mouse models. Conditional knockout of Stat3 in cells expressing Gfap reduced Gfap transactivation and prevented protein accumulation. Astrocyte-specific Stat3 knockout in adult mice with existing pathology reversed GFAP accumulation and aggregation. Preventing STAT3 activation reduced markers of reactive astrocytes, stress-related transcripts, and microglial activation, regardless of disease stage or genetic knockout approach. These results suggest that pharmacological inhibition of STAT3 could potentially reduce GFAP toxicity and provide a therapeutic benefit in patients with AxD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Waisman Center, University of Wisconsin-Madison, Madison, WI 53705, USA.
- Wyss Institute, Harvard University, Boston, MA 02115, USA.
- Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Department of Comparative Biosciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.
ORCID-Profile: Tracy L Hagemann, Albee Messing
Förderung
- NICHD NIH HHS
- NINDS NIH HHS
- NIH NINDS
- NICHD
- End Alexander disease
- Juanma Fund
Zitieren
APA
Hagemann, T. L., Coyne, S., Levin, A., Wang, L., Feany, M. B., & Messing, A. (2023). STAT3 Drives GFAP Accumulation and Astrocyte Pathology in a Mouse Model of Alexander Disease. Cells, 12(7), 978. https://doi.org/10.3390/cells12070978
Vancouver
Hagemann TL, Coyne S, Levin A, Wang L, Feany MB, Messing A. STAT3 Drives GFAP Accumulation and Astrocyte Pathology in a Mouse Model of Alexander Disease. Cells. 2023;12(7):978. doi:10.3390/cells12070978
BibTeX
@article{Hagemann2023,
author = {Hagemann, Tracy L and Coyne, Sierra and Levin, Alder and Wang, Liqun and Feany, Mel B and Messing, Albee},
title = {STAT3 Drives GFAP Accumulation and Astrocyte Pathology in a Mouse Model of Alexander Disease},
journal = {Cells},
year = {2023},
volume = {12},
number = {7},
pages = {978},
doi = {10.3390/cells12070978}
}
EUVIMED